Peer-reviewed veterinary case report
Best starting dexamethasone dose for dogs with MUO brain inflammation
By Prikryl, Miroslav et al.·Published in Frontiers in veterinary science·2025·Department of Neurology and Neurosurgery·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparison of 2.0 mg/kg/day and 0.5 mg/kg/day immunosuppressive dexamethasone protocols as initial treatment for dogs with MUO.
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with meningoencephalitis of unknown origin (MUO), a serious neurological condition, received either a low or high dose of dexamethasone, a corticosteroid used to reduce inflammation. Most dogs showed improvement in their neurological symptoms after four days of treatment, but a few experienced worsening conditions, including two that sadly passed away. While some dogs developed gastrointestinal issues, there was no clear difference in side effects between the two dosing groups. Overall, both doses appeared to help many dogs, but further research is needed to determine the best approach for treatment.
People also search for: dog meningoencephalitis treatment · dexamethasone for dogs side effects · dog neurological disorder symptoms
Abstract
INTRODUCTION: Canine meningoencephalitis of unknown origin (MUO) is a common immune-mediated neurological disorder primarily treated with corticosteroids. However, the optimal initial dosing regimen remains unclear. METHOD: This prospective, randomized, parallel-group study evaluated the short-term clinical efficacy and gastrointestinal (GIT) safety of two intravenous dexamethasone dosing protocols (0.5 mg/kg/day vs. 2.0 mg/kg/day) in dogs diagnosed with MUO. Neurological and GI scoring systems were used to assess outcomes over a four-day hospitalization period. RESULTS: Sixty dogs were enrolled and randomly assigned to either the 0.5 mg/kg/day ( = 30) or 2.0 mg/kg/day ( = 30) dexamethasone group. Neurological improvement was observed in 57 (95.0%) dogs, while 3 (5.0%) deteriorated, including 2 (3.3%) that died. No significant difference in neurological score changes was found between groups. Among the 58 survivors, 17 (28.3%) developed GIT signs, with 11 dogs in the 2.0 mg/kg/day group and 6 in the 0.5 mg/kg/day group. There was no significant difference in the incidence of GIT signs between groups, nor in the GIT score changes over time. DISCUSSION: This study has not identified a significant difference in short term outcome using different dosing protocols of dexamethasone in dogs diagnosed with MUO. Further studies with larger sample sizes and extended follow-up periods are warranted to investigate the potential dose-dependent effects of dexamethasone on both neurological and GIT outcomes.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40557268/